EGFR and squamous cell lung carcinoma: The aim of this study was to observe the efficacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with chemotherapy as second-or later-line in the treatment of advanced lung squamous cell carcinoma.